Test Reporting Updates Memorandum – Prenatal Chromosomal Microarray Analysis

Effective July 5, 2017, in a continuing effort to optimize our offerings, the following changes will be made to the prenatal Chromosomal Microarray Analysis (CMA) tests.
Our reporting policy for prenatal CMA has been updated, as shown in the detailed summary on page two. The major changes include:

  • Parental studies will be performed reflexively when necessary to help clarify the significance of the fetal results; for all other fetal findings, parental studies will be available on a fee-for-service basis.
  • Moving forward, uniparental disomy (UPD) studies for all chromosomes will be available on a feefor-service basis.

We have made updates to our requisition and consent forms. The major changes include:

  • Reflex testing options are now available.
  • The consent form has been updated to include options for receiving information about medically actionable findings.

The above changes apply to the following prenatal CMA tests:

  • Targeted CMA – Prenatal – Amniotic Fluid (TC 8656)/ CVS (TC 8657)
  • Expanded CMA – Prenatal – Amniotic Fluid (TC 8670)/ CVS (TC 8671)
  • Targeted CMA Limited Karyotype – Prenatal – Amniotic Fluid (TC 8673)/CVS (TC 8672)
  • Expanded CMA and Limited Karyotype – Prenatal – Amniotic Fluid (TC 8675)/ CVS (TC 8676)
Previous Post
Test Reporting Updates Memorandum – Exome
Next Post
Fluidigm Licenses CFTR Next-Generation Sequencing Assay From Baylor Genetics for Use With the Juno System

Menu